WANY
AMPH icon

Wealthspire Advisors (New York)’s Amphastar Pharmaceuticals AMPH Stock Holding History

Wealthspire Advisors (New York)’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-70
Closed -$1.87K – 1112
2025
Q3 		$1.87K Buy
+70
New +$1.81K ﹤0.01% 2625

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealthspire Advisors (New York)'s AMPH Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2025, closing a stake of 70 shares — an estimated $1.87K sold.

Wealthspire Advisors (New York) first reported a position in AMPH in Q3 2025 and held it in 1 quarter. The position peaked at $1.87K in Q3 2025. 235 funds tracked by Wall St. Rank hold AMPH as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Amphastar Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 70 Amphastar Pharmaceuticals shares in Q4 2025, an estimated $1.87K.
  • Wealthspire Advisors (New York) first reported a position in Amphastar Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Amphastar Pharmaceuticals position peaked at $1.87K in Q3 2025.
  • 235 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.